Middleton and Carlson discussed various product developments that were presented during the meeting, including NK-based cell therapies, various CAR T-cell therapies, directed evolution of capsid discovery, and plasmid DNA products, to name a few.
The two also discussed how several companies are working on the transition from small-scale boutique therapies to treatments for diseases that impact millions of people. This inclusive effort requires innovations in components such as viral vectors, stem cell, and allogeneic immunotherapies. Many organizations are attempting to scale up and automate as much of the manufacturing process as possible. Ultimately, as Middleton and Carlson discuss, the goal is to transition from a very hands-on, labor-intensive process to a more factory automated, large-scale process.
To stay up to date on the latest business happenings in the cell and gene therapy industry, check out Cell & Gene Therapy Business Outlook today!